Abstract
Behçet’s disease is a systemic inflammatory disorder without a specific treatment that is chosen on the basis of the type and severity of manifestation in the organ involved. More recently, biological agents like etanercept have emerged as possible therapeutic alternatives in patients resistant to conventional therapy. We describe the successful treatment for 1 year of resistant Behçet’s disease with etanercept. After the administration of this drug, a resolution of the clinical, laboratory and instrumental picture was achieved with a suspension of immunosuppressive treatments and a reduction of steroid dependency (5 mg/day). No side effects were observed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Gul A (2007) Standard and novel therapeutic approaches to Behçet’s disease. Drugs 67:2013–2022
Suzuki Kurokawa M, Suzuki N (2004) Behcet’s disease. Clin Exp Med 4:10–20
Sfikasis PP (2002) Behçet’s disease: a new target for anti-tumor necrosis factor treatment. Ann Rheum Dis 61(Suppl 2):51–53
Papp Ka, Keystone EC, Shear NH (2007) Mechanism of action, pharmacolokinetic and drug interection of Etanercept. Dermatology 11(Suppl 1):3–13
Scallon B, Cai A, Solowski N et al (2002) Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 301:418–426
Pipitone N, Olivieri I, Cantini F et al (2006) New approaches in the treatment of Adamantiades-Behçet’s disease. Curr Opin Rheumatol 18:3–9
Ohno S, Nakamura S, Hori S et al (2004) Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet’s disease with refractory uveoretinitis. J Rheumatol 31:1362–1368
Lee H, Kimko HC, Rogge M et al (2003) Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis. Clin Pharmacol Ther 73:348–365
Korth-Bradley JM, Rubin AS, Hanna RK et al (2003) The pharmacokinetics of etanercept in healthy volunteers. Ann Pharmacother 34:161–164
Zhou H (2005) Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. J Clin Pharmacol 45:490–497
Melikoglu M, Fresko I, Mat C et al (2005) Short-term trial of etanercept in Behçet’s disease: a double blind, placebo controlled study. J Rheumatol 32:98–105
Disclosures
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Curigliano, V., Giovinale, M., Fonnesu, C. et al. Efficacy of etanercept in the treatment of a patient with Behçet’s disease. Clin Rheumatol 27, 933–936 (2008). https://doi.org/10.1007/s10067-008-0857-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-008-0857-5